We are live on
!
Find out more
HS
HighVista Strategies Portfolio holdings
AUM
$362M
1-Year Est. Return
230.96%
This Fund
S&P 500
This Quarter
Est. Return
-6.86%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$166M
AUM Growth
+$8.35M
(+5.3%)
Cap. Flow
+$27.8M
Cap. Flow
% of AUM
16.81%
Top 10 Holdings %
Top 10 Hldgs %
40.91%
Holding
125
New
39
Increased
43
Reduced
18
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mastercard
MA
|
+$4.42M |
| 2 |
iShares Russell 1000 Value ETF
IWD
|
+$3.73M |
| 3 |
TGNA
TEGNA Inc
TGNA
|
+$3.12M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
+$2.8M |
| 5 |
TWTR
Twitter, Inc.
TWTR
|
+$2.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PBCT
People's United Financial Inc
PBCT
|
+$3.92M |
| 2 |
Fidelity National Information Services
FIS
|
+$3.85M |
| 3 |
CERN
Cerner Corp
CERN
|
+$3.49M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$1.5M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$979K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.47% |
| 2 | Technology | 22.39% |
| 3 | Financials | 16.85% |
| 4 | Communication Services | 4.29% |
| 5 | Consumer Discretionary | 2.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Iovance Biotherapeutics
IOVA
$2.9B
| $496K | 0.3% |
44,962
-9,439
| -17% | -$124K |
|
|
SWTX
77
DELISTED
SpringWorks Therapeutics
SWTX
| $470K | 0.28% |
19,080
+11,325
| +146% | +$414K |
|
78
Keros Therapeutics
KROS
$212M
| $459K | 0.28% |
16,623
+583
| +4% | +$25.6K |
|
79
PTC
PTC
$16.4B
| $458K | 0.28% |
+4,310
| New | +$465K |
|
80
Regenxbio
RGNX
$688M
| $404K | 0.24% |
+16,352
| New | +$409K |
|
81
Revolution Medicines
RVMD
$44.4B
| $403K | 0.24% |
+20,685
| New | +$403K |
|
|
ITOS
82
DELISTED
iTeos Therapeutics
ITOS
| $390K | 0.24% |
18,913
-3,899
| -17% | -$92.5K |
|
83
Neurocrine Biosciences
NBIX
$16.8B
| $367K | 0.22% |
+3,767
| New | +$348K |
|
84
Protagonist Therapeutics
PTGX
$9.71B
| $367K | 0.22% |
46,459
-45,586
| -50% | -$551K |
|
|
RNAM
85
DELISTED
Avidity Biosciences
RNAM
| $361K | 0.22% |
24,864
-28,300
| -53% | -$421K |
|
86
ServiceNow
NOW
$132B
| $348K | 0.21% |
+3,660
| New | +$349K |
|
87
T-Mobile US
TMUS
$191B
| $348K | 0.21% |
+2,588
| New | +$338K |
|
88
Madrigal Pharmaceuticals
MDGL
$11.9B
| $344K | 0.21% |
4,800
+275
| +6% | +$20.2K |
|
|
BLU
89
DELISTED
BELLUS Health Inc.
BLU
| $336K | 0.2% |
36,364
-28,810
| -44% | -$236K |
|
90
PMV Pharmaceuticals
PMVP
$65.6M
| $332K | 0.2% |
+23,324
| New | +$339K |
|
91
Bilibili
BILI
$7.95B
| $327K | 0.2% |
+12,770
| New | +$307K |
|
92
JD.com
JD
$45.2B
| $327K | 0.2% |
+5,098
| New | +$294K |
|
|
RXDX
93
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $304K | 0.18% |
+10,782
| New | +$313K |
|
94
Autodesk
ADSK
$54.1B
| $303K | 0.18% |
+1,766
| New | +$340K |
|
|
NBP
95
NovaBridge Biosciences American Depositary Shares
NBP
$205M
| $300K | 0.18% |
26,534
+1,132
| +4% | +$13.6K |
|
|
AVTA
96
DELISTED
Avantax, Inc. Common Stock
AVTA
| $293K | 0.18% |
+15,872
| New | +$289K |
|
97
Willis Towers Watson
WTW
$31.9B
| $291K | 0.18% |
+1,474
| New | +$316K |
|
98
Autoliv
ALV
$8.92B
| $281K | 0.17% |
+3,914
| New | +$293K |
|
99
Salesforce
CRM
$162B
| $277K | 0.17% |
+1,676
| New | +$296K |
|
100
Expedia Group
EXPE
$37.7B
| $246K | 0.15% |
+2,592
| New | +$367K |
|
Similar funds
SIAG
MS
WI
WTFG
VIA
A6
PI
ACM
HighVista Strategies's Q2 2022 Portfolio in Review
As of Q2 2022, HighVista Strategies held 125 positions worth $166M, up 5.3% from $157M the previous quarter. Its ten largest holdings account for 41% of the portfolio.
HighVista Strategies deployed $27.8M of net new capital in Q2 2022, opening 39 new positions and adding to 43 existing holdings. Its largest new stake was iShares Russell 1000 Value ETF: 23,825 shares worth $3.45M.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 44% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $551K trimmed.
- HighVista Strategies's largest Q2 2022 buy was iShares Russell 1000 Value ETF: 23,825 shares worth $3.45M.
- HighVista Strategies added most to Mastercard in Q2 2022, an estimated $4.42M increase.
- HighVista Strategies's biggest Q2 2022 reduction was Protagonist Therapeutics, cutting an estimated $551K.
- HighVista Strategies fully exited People's United Financial Inc in Q2 2022, selling an estimated $3.92M.
- HighVista Strategies's ten largest holdings make up 41% of its $166M portfolio in Q2 2022.
- HighVista Strategies opened 39 new positions and closed 15 in Q2 2022.
- HighVista Strategies's portfolio value rose 5.3% quarter-over-quarter to $166M.
Based on HighVista Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.